Company news
Black Diamond Therapeutics, Inc. news in 2022
Black Diamond Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
December 11, 2022
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 25, 2022
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 2, 2022
Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
June 5, 2022
Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
May 31, 2022
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine
May 11, 2022
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment
April 24, 2022
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer
April 17, 2022
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
April 6, 2022
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors
April 6, 2022
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
March 1, 2022
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
February 21, 2022
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
January 10, 2022
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022
January 9, 2022
Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Decks in 2022
- Investor Presentation (April 2022)
Investor deck · 38 slides · Apr 25, 2022
- Investor Presentation (January 2022)
Investor deck · 39 slides · Jan 10, 2022